Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
November 18, 2024 07:00 ET
|
https://immatics.com/
The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Today, Company discloses first clinical...
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 14, 2024 16:30 ET
|
Marker Therapeutics
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
EvolveImmune Therapeutics Presents New Preclinical and Translational Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 11, 2024 07:00 ET
|
EvolveImmune
Poster Presentations Spotlight Differentiated Therapeutic Profile and Precision Therapeutic Strategy for Lead Development Candidate EVOLVE104 as Program Advances Toward Clinic for Solid Tumors EVOLVE...
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
November 08, 2024 17:00 ET
|
https://immatics.com/
Two oral presentations and multiple posters on clinical andpreclinical-stage candidates to be presented at SITC, demonstratingthe strength of Immatics’ TCR-T PRAME franchise to target solid cancers ...
Nouscom’s Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to ‘Intercept’ Cancer
November 05, 2024 09:01 ET
|
Nouscom Srl
Lynch Syndrome (LS) is a common hereditary condition (affecting one in 300) conferring a high risk of developing colorectal, gastric, endometrial and other cancers NOUS-209 monotherapy is well...
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
October 31, 2024 08:00 ET
|
EvolveImmune
NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to...
EvolveImmune Therapeutics to Present New Preclinical Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 23, 2024 07:00 ET
|
EvolveImmune
Multiple Presentations on Lead Development Candidate EVOLVE104 to Showcase Preclinical Safety and Efficacy Profile and Precision Therapeutic Strategy as Company Advances Program Toward Clinic for...
Immatics Announces Pricing of $150 Million Public Offering
October 10, 2024 20:50 ET
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Immatics Announces Proposed $150 Million Public Offering
October 10, 2024 07:30 ET
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
October 10, 2024 06:30 ET
|
https://immatics.com/
Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily...